Mesenchymal stem cell-based therapy for autoimmune diseases: emerging roles of extracellular vesicles

Rad, Fariba; Ghorbani, Mohammad; Roushandeh, Amaneh Mohammadi; Roudkenar, Mehryar Habibi

doi:10.1007/s11033-019-04588-y

Cited by 74 publications

(51 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These benefits are attributed to MSCs paracrine effects, above all to their ability to regulate the immune system. MSCs may help for AA treatment, especially for autoimmune type [11].…”

Section: Allogeneic Transplantation and Alternative Methods For Aa Trmentioning

confidence: 99%

“…A new viable alternative for the treatment of AA has been sought and the use of mesenchymal stem (MSCs) therapy may be a promising therapeutic candidate mainly because of their hypoimmunogenicity and the lack of rejection after transplants and immunomodulatory effects, which may promote decreasing the symptoms of the disease [9,10]. These benefits are attributed to the paracrine effects, above all by its ability to regulate the immune system [11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Alternative Immune-Mediated-Based Methods in the Aplastic Anemia Treatment

Gonzaga¹,

Policiquio²,

Wenceslau³

et al. 2021

Human Blood Group Systems and Haemoglobinopathies

View full text Add to dashboard Cite

Acquired aplastic anemia (AA) is characterized by partial or total bone marrow (BM) destruction resulting in pancytopenia. Most of the acquired AA is the result of autoimmune condition the imbalance between T-regulatory cells (Treg), abnormal cytokines production and cytotoxic T cells activation, leading to the hematopoietic stem cells (HSCs) death. The first-line treatment is given by HSC transplant, but some patients did not respond to the treatment. Therefore, new technologies need to treat AA nonresponder patients. Studies are in progress to test the efficacy of stem cell-based therapeutic as mesenchymal stem cells (MSCs), which confer low immunogenicity and are reliable allogeneic transplants in refractory severe AA cases. Furthermore, MSCs comprise the BM stromal niche and have an important role in supporting hematopoiesis by secreting regulatory cytokines, providing stimulus to natural BM microenvironment. In addition, MSCs have immunomodulatory property and are candidates for efficient supporting AA therapy.

show abstract

“…These benefits are attributed to MSCs paracrine effects, above all to their ability to regulate the immune system. MSCs may help for AA treatment, especially for autoimmune type [11].…”

Section: Allogeneic Transplantation and Alternative Methods For Aa Trmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Alternative Immune-Mediated-Based Methods in the Aplastic Anemia Treatment

Gonzaga¹,

Policiquio²,

Wenceslau³

et al. 2021

Human Blood Group Systems and Haemoglobinopathies

View full text Add to dashboard Cite

show abstract

“…Several studies indicated that exosomes could serve as a novel mechanism to transfer miRNAs between cells to regulate gene expression offering therapeutic effects for liver [85], fibrosis [86], stroke [87], and cardiovascular diseases [88,89]. Moreover, MSC-EVs therapeutic effects have also been described for the adaptive and innate immune response [90]. A variety of studies have examined the immunoregulatory function of MSC-EVs in autoimmune disease models such as autoimmune murine models of type 1 diabetes, experimental autoimmune uveoretinitis, collagen-induced arthritis, synovitis and multiple sclerosis [26].…”

Section: Msc-derived Extracellular Vesiclesmentioning

confidence: 99%

“…In addition, EVs present many advantages, including low immunogenicity, lack endogenous tumor-formation potential, in vivo stability, and high delivery efficiency. However, the dose of injected EVs and the route of administration affected their biodistribution pattern [90]. Further studies to better understand the mechanisms underlying MSC-EVs functions are necessary for future EVs-based therapy in the clinic.…”

Section: Msc-derived Extracellular Vesiclesmentioning

confidence: 99%

Role of Mesenchymal Stromal Cells as Therapeutic Agents: Potential Mechanisms of Action and Implications in Their Clinical Use

Jimenez-Puerta

Marchal

López‐Ruiz

et al. 2020

JCM

View full text Add to dashboard Cite

Due to the great therapeutic interest that involves the translation of mesenchymal stromal cells (MSCs) into clinical practice, they have been widely studied as innovative drugs, in order to treat multiple pathologies. MSC-based cell therapy involves the administration of MSCs either locally or systemically into the receptor body where they can traffic and migrate towards the affected tissue and participate in the process of healing. The therapeutic effects of MSCs compromise of different mechanisms such as the functional integration of differentiated MSCs into diseased host tissue after transplantation, their paracrine support, and their impact on the regulation of both the innate and the acquired immune system. Here, we establish and provide recent advances about the principal mechanisms of action through which MSCs can perform their activity and effect as a therapeutic tool. The purpose of this review is to examine and discuss the MSCs capacity of migration, their paracrine effect, as well as MSC-mediated modifications on immune cell responses.

show abstract

“…Therapeutic transplantation of stem/progenitor cells has been experimentally applied in the treatment of a variety of medical conditions with encouraging results, including inflammatory bowel diseases (Kang et al 2018), renal diseases (Sun et al 2019), autoimmune diseases (Rad et al 2019) and periodontitis (Fawzy El-Sayed et al 2012, 2015a. Ongoing advances in tissue engineering carrier/scaffolds, biomolecules and cellular transplantation approaches may have paved the way for a stem/progenitor cellmediated pulpal regeneration, too (Fawzy El-Sayed et al 2015a,b, Conde et al 2016, Galler 2016.…”

Section: Introductionmentioning

confidence: 99%

Stem/progenitor cell‐mediated pulpal tissue regeneration: a systematic review and meta‐analysis

et al. 2019

View full text Add to dashboard Cite

Background Stem/progenitor cell‐mediated pulpal regeneration could represent a promising therapeutic alternative in the field of clinical endodontics. Aim The present study aimed to systematically assess and meta‐analyse dental pulpal tissue regeneration, pulpal vitality and apical healing after the transplantation of stem/progenitor cells versus no transplantation. Data sources MEDLINE, Cochrane CENTRAL and EMBASE were searched up to January 2019 for animal experiments and human trials evaluating the pulpal transplantation of stem/progenitor cells. Cross‐referencing and hand search were additionally performed. Study eligibility criteria, participants and interventions Based on randomized controlled clinical trials (RCTs) or controlled clinical trials (CCTs), conducted in animals or humans, the effect of the transplantation of stem/progenitor cells compared to no transplantation on pulpal tissue regeneration, pulpal vitality and apical healing was examined. Study appraisal and synthesis methods The primary outcome was histologically determined pulpal tissue regeneration, whilst pulpal vitality and apical healing were secondary outcomes. The SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) guidelines and the revised Cochrane risk of bias tool (RoB 2.0) were used for risk‐of‐bias assessment. Pooled standardized differences in means (SDM) and 95% confidence intervals (95% CI) were calculated using random‐effects meta‐analyses. Results From 2834 identified articles, eight animal experiments (82 animals with 336 experimental pulpal defects) and one human trial (40 humans with 40 pulpal defects) were included. Risk of bias of most animal studies was high, whilst the human trial revealed ‘some concerns’. Stem/progenitor cell‐transplanted pulps demonstrated significantly increased pulpal tissue regeneration compared with controls (SDM [95%CI]: 6.29 [3.78–8.80]). Limitations Data on pulpal vitality and apical healing were sparse and inconsistent. Heterogeneity across studies was substantial, publication bias was present, and mainly indirect, surrogate outcome measures were applied. The overall strength of evidence was very low. Conclusions and implications of key findings The transplanation of stem/progenitor cells shows promise for pulp regeneration, whilst clinical routine application is still not in reach. Further investigations, employing a comprehensive set of outcomes including those demonstrating functional pulp regeneration relevant for patient‐centred care, are required.

show abstract

Mesenchymal stem cell-based therapy for autoimmune diseases: emerging roles of extracellular vesicles

Cited by 74 publications

References 150 publications

Alternative Immune-Mediated-Based Methods in the Aplastic Anemia Treatment

Alternative Immune-Mediated-Based Methods in the Aplastic Anemia Treatment

Role of Mesenchymal Stromal Cells as Therapeutic Agents: Potential Mechanisms of Action and Implications in Their Clinical Use

Stem/progenitor cell‐mediated pulpal tissue regeneration: a systematic review and meta‐analysis

Contact Info

Product

Resources

About